DOI: https://doi.org/10.22263/2312-4156.2026.3.9
M.R. Konorev, R.A. Pavlyukov
Improving skills of using nonsteroid anti-inflammatory drugs in clinical practice
Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
Vestnik VGMU. 2026;25(3):9-18.
Abstract.
Nonsteroidal anti-inflammatory drugs (NSAIDs) remain among the most widely used medications in clinical practice due to their anti-inflammatory, analgesic, and antipyretic effects. However, their use is associated with a significant risk of adverse drug reactions, including potentially life-threatening complications, which limits long-term therapy. In this review particular attention is paid to risk factors for NSAID-associated complications and to patients’ stratification according to gastrointestinal and cardiovascular risk. The review outlines contemporary strategies for the prevention of NSAID-induced gastrointestinal and cardiovascular complications during long-term therapy, including rational drug selection and the use of gastroprotective agents. Individualized NSAID therapy based on a comprehensive risk assessment may improve treatment safety and clinical outcomes.
Keywords: nonsteroidal anti-inflammatory drugs, NSAIDs, cyclooxygenase, COX-1, COX-2, adverse drug reactions, gastrointestinal complications, cardiovascular risk, gastroprotection, risk stratification, long-term NSAID therapy.
References
1. Ricciotti E, Fitzgerald GA. Prostaglandins and inflammation. Arteriosclerosis Thrombosis and Vascular Biology. 2011 May;31(5):986-1000. doi: http://dx.doi.org/10.1161/ATVBAHA.110.207449
2. Huang J, Hunt RH. A clinician's view of strategies for preventing NSAID-induced gastrointestinal ulcers. Inflammopharmacology. 1996;4:17-30.
3. Ko KA, Lee DK. Nonsteroidal Anti-Inflammatory Drug-Induced Peptic Ulcer Disease. The Korean Journal of Helicobacter and Upper Gastrointestinal Research. 2025 Mar;25(1):34-41. doi: http://dx.doi.org/10.7704/kjhugr.2025.0004
4. Paakkari H. Epidemiological and financial aspects of the use of non-steroidal anti-inflammatory analgesics. Pharmacology and Toxicology. 1994:75 Suppl 2:56-59. doi: http://dx.doi.org/10.1111/j.1600-0773.1994.tb01999.x
5. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. The Journal of Rheumatology. 1999 Apr:56:18-24.
6. Kikuchi S, Togo K, Ebata N, A retrospective database study of gastrointestinal events and medical costs associated with nonsteroidal anti-inflammatory drugs in Japanese patients of working age with osteoarthritis and chronic low back pain. Pain Medicine. 2021 May;22(5):1029-1038. doi: http://dx.doi.org/10.1093/pm/pnaa421
7. Smalley WE, Griffin MR. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterology Clinics of North America. 1996 Jun;25(2):373-396. doi: http://dx.doi.org/10.1016/s0889-8553(05)70253-3
8. Vane JR, Botting RM. Mechanism of action of antiinflammatory drugs. International Journal of Tissue Reactions. 1998;20(1):3-15.
9. Panchal NK, Sabina EP. Non-steroidal anti-inflammatory drugs (NSAIDs): A current insight into its molecular mechanism eliciting organ toxicities. Food and Chemical Toxicology. 2023 Feb:172:113598. doi: http://dx.doi.org/10.1016/j.fct.2022.113598
10. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. The American Journal of Medicine. 1998 Mar;104(3A):2S-8S. doi: http://dx.doi.org/10.1016/s0002-9343(97)00203-9
11. Ahmadi M, Bekeschus S, Weltmann KD, von Woedtke T, Wende K. Non-steroidal anti-inflammatory drugs: Recent advances in the use of synthetic COX-2 inhibitors. RSC Medicinal Chemistry. 2022 Feb;13(5):471-496. doi: http://dx.doi.org/10.1039/d1md00280e
12. Janssen M, Dijkmans BA, Vandenbroucke JP, Biemond I, Lamers CB. Achlorhydria does not protect against benign upper gastrointestinal ulcers during NSAID use. Digestive Diseases and Sciences. 1994 Feb;39(2):362-365. doi: http://dx.doi.org/10.1007/BF02090209
13. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proceedings of the National Academy of Sciences of the United States of America. 1999 Jan;96(1):272-277. doi: http://dx.doi.org/10.1073/pnas.96.1.272
14. Mead EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclo-oxygenase) isozymes by aspriin and other non-steroidal anti-inflammatory drugs. The Journal of Biological Chemistry. 1993 Mar;268(9):6610-6614.
15. Patrono C. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. British Journal of Clinical Pharmacology. 2016 Oct;82(4):957-964. doi: http://dx.doi.org/10.1111/bcp.13048
16. Armstrong RA. Platelet prostanoid receptors. Pharmacology & Therapeutics. 1996;72(3):171-191. doi: http://dx.doi.org/10.1016/s0163-7258(96)00103-9
17. Mardini IA, Fitzgerald GA. Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs. Molecular Interventions. 2001 Apr;1(1):30-38.
18. Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. British Journal of Pharmacology. 1999 Nov;128(6):1121-1132. doi: http://dx.doi.org/10.1038/sj.bjp.0702897
19. Chahal S, Rani P, Kiran CHS, Sindhu J, Joshi G, Ganesan A. Design and development of COX-II inhibitors: current scenario and future perspective. ACS Omega. 2023 May;8(20):17446-17498. doi: http://dx.doi.org/10.1021/acsomega.3c00692
20. Negishi M, Sugimoto Y, Ichikawa A. Molecular mechanisms of diverse actions of prostanoid receptors. Biochimica et Biophysica Acta. 1995 Oct;1259(1):109-119. doi: http://dx.doi.org/10.1016/0005-2760(95)00146-4
21. Pierce KL, Regan JW. Prostanoid receptor heterogeneity through alternative mRNA splicing. Life Sciences. 1998;62(17-18):1479-1483. doi: http://dx.doi.org/10.1016/s0024-3205(98)00093-9
22. Van Ryn J, Trummlitz G, Pairet M. COX-2 selectivity and inflammatory processes. Current Medicinal Chemistry. 2000 Nov;7(11):1145-1161. doi: http://dx.doi.org/10.2174/0929867003374255
23. Ju, Z, Li M, Xu J, Howell DC, Li Z, Chen FE. Recent development on COX-2 inhibitors as promising anti-inflammatory agents: the past 10 year. Acta Pharmaceutica Sinica B. 2022 Jun;12(6):2790-2807. doi: http://dx.doi.org/10.1016/j.apsb.2022.01.002
24. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB Journal. 2004 May;18(7):790-804. doi: http://dx.doi.org/10.1096/fj.03-0645rev
25. Warner TD, Vojnovic I, Giuliano F, Jiménez R, Bishop-Bailey D, Mitchell JA. Cyclooxygenases 1, 2, and 3 and the production of prostaglandin I2: investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissues. The Journal of Pharmacology and Experimental Therapeutics. 2004 Aug;310(2):642-627. doi: http://dx.doi.org/10.1124/jpet.103.063875
26. Karateev AE, Nasonov EL, Yakhno NN, Ivashkin VT, Chichasova NV, Alekseeva LI, i dr. Clinical Guidelines "Rational use of non-steroidal anti-inflammatory drugs (NSAIDs) in clinical practice". Sovremennaya Revmatologiya. 2015;9(1):4-23. (In Russ.). doi: http://dx.doi.org/10.14412/1996-7012-2015-1-4-23
27. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. JAMA. 2006 Oct;296(13):1633-1644. doi: http://dx.doi.org/10.1001/jama.296.13.jrv60011
28. Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S. Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clinical Therapeutics. 2006 Aug;28(8):1123-1132. doi: http://dx.doi.org/10.1016/j.clinthera.2006.08.014
29. Tiwari V, Shandily S, Albert J, Mishra V, Dikkatwar M, Singh R, et al. Insights into medication-induced liver injury: understanding and management strategies. Toxicology Reports. 2025 Mar:14:101976. doi: http://dx.doi.org/10.1016/j.toxrep.2025.101976
30. O’Connor N, Dargan PI, Jones AL. Hepatocellular damage from non-steroidal anti-inflammatory drugs. Quarterly Journal of Medicine. 2003 Nov;96(11):787-791. doi: http://dx.doi.org/10.1093/qjmed/hcg138
31. Sriutta P, Sirichanchuen B, Permsuwan U. Hepatotoxicity of nonsteroidal anti-inflammatory drugs: a systematic review of randomized controlled trials. International Journal of Hepatology. 2018 Jan:2018:5253623. doi: http://dx.doi.org/10.1155/2018/5253623
32. Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiology and Drug Safety. 2014 Jan;23(1):43-50. doi: http://dx.doi.org/10.1002/pds.3463
33. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Annals of Internal Medicine. 1991 Nov;115(10):787-796. doi: http://dx.doi.org/10.7326/0003-4819-115-10-787
34. Hawkey CJ, Laine L, Harper SE, Quan HU, Bolognese JA, Mortensen E. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Alimentary Pharmacology and Therapeutics. 2001 Oct;15(10):1593-601. doi: http://dx.doi.org/10.1046/j.1365-2036.2001.01007.x
35. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Archives of Internal Medicine. 2000 Jul;160(14):2093-2099. doi: http://dx.doi.org/10.1001/archinte.160.14.2093
36. Koch M, Dezi A, Tarquini M, Capurso L. Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: risk factors for serious complications. Digestive and Liver Disease. 2000 Mar;32(2):138-151. doi: http://dx.doi.org/10.1016/s1590-8658(00)80402-8
37. Lai KC, Chu KM, Hui WM, Wong BCY, Hu WHC. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. The American Journal of Medicine. 2005 Nov;118(11):1271-1278. doi: http://dx.doi.org/10.1016/j.amjmed.2005.04.031
38. Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology. 2002 Oct;123(4):1006-1012. doi: http://dx.doi.org/10.1053/gast.2002.36013
39. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Archives of Internal Medicine Research. 2000 Mar;160(6):777-784. doi: http://dx.doi.org/10.1001/archinte.160.6.777
40. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. 1995 Aug;123(4):241-249. doi: http://dx.doi.org/10.7326/0003-4819-123-4-199508150-00001
41. Simon LS, Hatoum HT, Bittman RM, Archambault WT, Polisson RP. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Family Medicine. 1996 Mar;28(3):204-210.
42. Najm WI. Peptic ulcer desease. 2011 Sep;38(3):383-394. doi: http://dx.doi.org/10.1016/j.pop.2011.05.001
43. Tannenbaum H, Davis P, Russell AS, Atkinson MH, Maksymowych W, Huang SH, et al. An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Canadian Medical Association Journal. 1996 Jul;155(1):77-88.
44. Chan FK, To KF, Wu JCY, Yung MY, Leung WK, Kwok T, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002 Jan;359(9300):9-13. doi: http://dx.doi.org/10.1016/s0140-6736(02)07272-0
45. Davidovic M, Svorcan P, Milanovic P, Antovic A, Milosevic D. Specifics of Helicobacter pylori infection/NSAID effects in the elderly. Romanian Journal of Gastroenterology. 2005 Sep;14(3):253-258.
46. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994 Mar;343(8900):769-772. doi: http://dx.doi.org/10.1016/s0140-6736(94)91843-0
47. Goldstein JL, Huang B, Amer F, Christopoulos NG. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. Clinical Therapeutics. 2004 Oct;26(10):1637-1643. doi: http://dx.doi.org/10.1016/j.clinthera.2004.10.002
48. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Annals of Internal Medicine. 1991 Feb;114(4):257-263. doi: http://dx.doi.org/10.7326/0003-4819-114-4-257
49. Henry D, Lim LL, Garcia Rodriguez LA, Carson JL, Griffin M, Savage R, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996 Jun;312(7046):1563-1566. doi: http://dx.doi.org/10.1136/bmj.312.7046.1563
50. Holtmann G, Howden CW. Review article: management of peptic ulcer bleeding-the roles of proton pump inhibitors and Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics. 2004 Feb:19 Suppl 1:66-70. doi: http://dx.doi.org/10.1111/j.0953-0673.2004.01841.x
51. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease: a meta-analysis. Lancet. 2002 Jan;359(9300):14-22. doi: http://dx.doi.org/10.1016/S0140-6736(02)07273-2
52. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology. 2004 Aug;127(2):395-402. doi: http://dx.doi.org/10.1053/j.gastro.2004.05.001
53. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994 Apr;343(8905):1075-1078. doi: http://dx.doi.org/10.1016/s0140-6736(94)90185-6
54. Moore N, Charlesworth A, van Ganse E, LeParc JM, Jones JK, Wall R, et al. Risk factors for adverse events in analgesic drug users: results from the PAIN study. Pharmacoepidemiology and Drug Safety. 2003 Oct-Nov;12(7):601-610. doi: http://dx.doi.org/10.1002/pds.842
55. Papatheodoridis GV, Archimandritis AJ. Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug users. World Journal of Gastroenterology. 2005 Jul;11(25):3811-3816. doi: http://dx.doi.org/10.3748/wjg.v11.i25.3811
56. Papatheodoridis GV, Papadelli D, Cholongitas E, Vassilopoulos D, Mentis A, Hadziyannis SJ. Effect of Helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs. The American Journal of Medicine. 2004 May;116(9):601-605. doi: http://dx.doi.org/10.1016/j.amjmed.2003.10.040
57. Serebruani VL, Steinhubl SR, Berger PB, Malinin AI, Baggish JS, Bhatt DL, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. The American Journal of Cardiology. 2005 May;95(10):1218-1222. doi: http://dx.doi.org/10.1016/j.amjcard.2005.01.049
58. Schorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Archives of Internal Medicine. 1993 Jul;153(14):1665-1670.
59. Sibilia J, Ravaud P, Marck G. Risk factors for gastrointestinal bleeding associated with low-dose aspirin. La Presse Médicale. 2003 Nov;32(37 Pt 2):S9-16.
60. Vergara M, Catalán M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Alimentary Pharmacology and Therapeutics. 2005 Jun;21(12):1411-1418. doi: http://dx.doi.org/10.1111/j.1365-2036.2005.02444.x
61. Pavlyukov RA, Konorev MR. Risk assessment of gastrointestinal erosion and ulcers induced by meloxicam in Helicobacterpylori-positive patients with seropositive and seronegative rheumatoid arthritis. Vestnik Vitebskogo Gosudarstvennogo Meditsinskogo Universiteta. 2018;17(4):55-63. (In Russ.).
62. Pavlyukov RA, Konorev MR. Risk assessment of gastrointestinal erosion and ulcers induced by meloxicam in patients with seropositive and seronegative rheumatoid arthritis. Rossiiskii Zhurnal Gastroenterologii Gepatologii Koloproktologii. 2019;29(2):45-52. (In Russ.). doi: http://dx.doi.org/10.22416/1382-4376-2019-29-2-45-52
63. Pavlyukov RA, Konorev MR, Sazonov MV. Prediction of the risk of undesired reactions (gastrointestinal erosion and ulcers) in patients with rheumatoid arthritis receiving meloxicam. Vestnik Farmatsii. 2025;(3):58-68. (In Russ.).
64. Pavlyukov RA, Konorev MR. Rheumatoid factor: risk assessment of gastroapatia induced by non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis. Lechebnoe Delo. 2017;(6):16-19. (In Russ.).
65. Dubois R, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Alimentary Pharmacology and Therapeutics. 2004 Jan;19(2):197-208. doi: http://dx.doi.org/10.1111/j.0269-2813.2004.01834.x
66. Chung RT, Rubin DT, Wilcox M, ed. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management: in 2 vol. 12th ed. Philadelphia: Elsevier; 2026. 2 vol.
67. Gargallo C, Sostres C, Lanas A. Prevention and treatment of NSAID gastropathy. Current Treatment Options in Gastroenterology. 2014 Dec;12(4):398-413. doi: http://dx.doi.org/10.1007/s11938-014-0029-4
Submitted 09.02.2026
Accepted 19.06.2026
Information about authors:
M.R. Konorev – Doctor of Medical Sciences, professor, head of the Chair of General & Clinical Pharmacology with the course of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University;
Roman A. Pavlyukov – senior lecturer of the Chair of General & Clinical Pharmacology with the course of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University, e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра..
